Genetron Health is a world-leading expert in precision medicine. We are committed to developing health management products that cover all elements of full-cycle cancer clinical treatment (including risk assessment, early screening, molecular pathology diagnosis, medication guidance and prognosis monitoring) and effectively applying genomic data to assist medical experts and research scientists. Additionally, we provide cancer patients and high-risk and healthy individuals with reliable molecular clinical services and professional cancer genetic risk assessment.In just three years, Genetron Health has built global genomics sequencing and bioinformatics platforms, established two research and development centers in both North Carolina, U.S., and Beijing, China, and set up clinical laboratories in Beijing, Shanghai, Hangzhou and Chongqing of over 10,000 square meters.In the future, Genetron Health will spread its sales network throughout China with professional marketing, product management, medical experts and scientific research teams, and will provide service for Chinese and global cancer patients with its strong foundation in cancer genomics and efficient clinical translation.
The international team at Genetron Health has numerous publications in top scientific journals and holds various cutting-edge patents. They are the results of more than 20 years of expertise in cancer genomics and translational medicine. With experts in the fields of cancer genomics, molecular biology, bioinformatics, pharmacology, clinical pathology and clinical medicine, our multidisciplinary team is able to develop many pioneering molecular diagnostic technologies and revolutionary bioinformatics platforms.
Chief Scientific Officer
Chief Executive Officer
Chief Operating Officer
Distinguished expert from China’s “Thousand Talents Program” Experienced entrepreneur and investor in biomedical field.
2013 Beijing Pangenomics Technology,Co. Ltd. was founded.
Genetron Health and Beijing Tiantan Hospital co-published a paper in Nature Genetics.
Genetron Health and the Chinese Academy of Medical Sciences Cancer Hospital co-published a paper in Nature Genetics.
Genetron Health and Fudan University Huashan Hospital co-published a paper in Cell Research.
Genetron Health and Zhejiang Peoples Hospital co-published a paper in the European Journal of Cancer.
Genetron Health (Beijing) Co. Ltd was founded (reorganization).
Genetron Health and Fudan University Huashan Hospital co-published a paper in Oncotarget.
Hangzhou Clinical Laboratory put into operation
Hangzhou Clinical Laboratory was put into operation.
Genetron Health established a center in Research Triangle Park, North Carolina, U.S.
Genetron Health and Zhejiang Peoples Hospital co-published a paper in Oncotarget.
Beijing Clinical Laboratory started operations.
Genetron Health (Chongqing) Co. Ltd was founded.
Shanghai Clinical Laboratory started operations.
Genetron Health signed a strategic partnership agreement with Thermo Fisher Scientific to build a joint research and development center.
Approved by National Development and Reform Commission, Genetron Health is to establish a National Demonstration Center for Genetic Testing Technologies.
Genetron Health finished Round B financing of hundreds of millions of RMB.
Promoted by the Municipal Science & Technology Commission, Beijing Life Science and Health Collaborative Innovation Joint Body was launched
Beijing Genetron Health Clinical Laboratories passed the PT Project of CAP (College of American Pathologists) with a full score
Genetron Health and Zhejiang Provincial Peoples Hospital co-published a paper in Oncotarget
Chongqing Jinchuang Genetron Clinical Laboratories were put into operation
Genetron Health obtained the "High-tech Enterprise Certificate" jointly issued by Beijing Municipal Science & Technology Commission and other departments
Genetron Health obtained the "Patent Trial Certificate" issued by Beijing Intellectual Property
Genetron Health and Huashan Hospital Fudan University co-published a paper in The American Journal of Human Genetics
Beijing Genetron Health Clinical Laboratories obtained CAP (College of American Pathologists) certification through first pass
<Human-TERT Gene Promoter Mutation Detection Kit (PCR-Fluorescent Probe Method)> and <Human-IDH1 Gene Mutation Detection Kit (PCR-Fluorescent Probe Method)>: The two representative and innovative products were displayed in the Exhibition of Ad
Genetron Healths biochip reader GENETRON 3D had received the approval of the Registration Certificate for Medical Device (Registration No.: YXZZ 20172400136)
2017 Deloitte-China Renaissance Rising Star for Genetron Health
The CLIA certificate by the Centers for Medicare and Medicaid Services (CMS) for Beijing Genetron Health Clinical Laboratories
“Genetron” is derived from the term of Darwin's “pangenesis”, which was known as the real source of the term “gene”. In other words, the “Genetron” is the most primitive definition of genetic material from human beings. With the concept of “tracing for the the roots of cancer genes”, Genetron came into being.
Continuous innovation in cancer genomics research, ultimately curing cancer.
Providing healthy people, high-risk individuals and cancer patients with world-leading, personalized and accurate full-cycle cancer health management plans, eventually becoming the industry leader in technology development.
Dream, Action, Innovation, Win-Win.